©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Regulation of Interaction of ras p21 with RalGDS and Raf-1 by Cyclic AMP-dependent Protein Kinase (*)

(Received for publication, June 7, 1995; and in revised form, October 2, 1995)

Akira Kikuchi (1)(§) Lewis T. Williams (1) (2)(¶)

From the  (1)Cardiovascular Research Institute and Daiichi Research Center, University of California, San Francisco, California 94143-0130 and the (2)Chiron Corporation, Emeryville, California 94608

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

RalGDS is a GDP/GTP exchange protein for ral p24, a member of small GTP-binding protein superfamily. We have recently shown that RalGDS interacts directly with the GTP-bound active form of ras p21 through the effector loop of ras p21 in vitro, in insect cells and in the yeast two-hybrid system. These results suggest that RalGDS functions as an effector protein of ras p21. Here, we report that RalGDS interacts with ras p21 in mammalian cells in response to an extracellular signal. Epidermal growth factor (EGF) induced the interaction of c-ras p21 and RalGDS in COS cells expressing both proteins, but not in the cells expressing RalGDS and c-ras p21, which is an effector loop mutant of ras p21. We also found that cyclic AMP-dependent protein kinase (protein kinase A) regulated the selectivity of ras p21-binding to either RalGDS or Raf-1. Protein kinase A phosphorylated RalGDS as well as (1-149)Raf (amino acid residues 1-149). Although the phosphorylated (1-149)Raf had a lower affinity for ras p21 than the unphosphorylated (1-149)Raf, both the phosphorylated and unphosphorylated RalGDS had the similar affinities for ras p21. The phosphorylation of RalGDS did not affect its activity to stimulate the GDP/GTP exchange of ral p24. Pretreatment of COS cells with forskolin further stimulated the interaction of ras p21 and RalGDS induced by EGF under the conditions that EGF-dependent Raf-1 activity was inhibited. These results indicate that ras p21 distinguishes between RalGDS and Raf-1 by their phosphorylation by protein kinase A.


INTRODUCTION

ras p21 is a member of the small GTP-binding protein superfamily and plays a pivotal role in cell growth and differentiation (1, 2) . ras p21 has GDP/GTP-binding and GTPase activity and cycles between the GDP-bound inactive and GTP-bound active forms. Recent studies have shown that growth factor receptors that have tyrosine kinase activity regulate the GDP/GTP exchange reaction and modulate the activity of ras p21(3, 4) . Growth factors such as EGF (^1)and platelet-derived growth factor induce autophosphorylation of their receptors and create specific binding sites for Src homology 2-containing proteins such as Grb2, phospholipase C, and the p85 subunit of PI 3-kinase(3, 5) . Grb2 is in a complex with Sos, a GDP/GTP exchange protein for ras p21, in cytosol in the absence of growth factors(6, 7, 8) . After a growth factor induces the autophosphorylation of its receptor, Grb2-Sos complex translocates from cytosol and associates with the receptor in membranes, thereby placing it in the vicinity of ras p21. Sos stimulates the conversion of the GDP-bound inactive form of ras p21 to the GTP-bound active form. The GTP-bound active form of ras p21 then transduces a signal(s) to downstream effector protein(s).

One identified effector protein is Raf-1, a serine/threonine kinase (9, 10, 11, 12, 13, 14, 15, 16) . ras p21 interacts directly with Raf-1 and activates Raf-1, although the detailed mechanism of activation is not known. Then Raf-1 activates mitogen-activated protein kinase kinase, which in turn activates extracellular signal-regulated kinase, and Raf-1 exerts its function through this protein kinase cascade(9, 10, 17, 18, 19) . These data are consistent with previous observations that Raf-1 acts downstream of ras p21 in signaling pathways that mediate both the growth and differentiation responses to receptor tyrosine kinases(20, 21, 22) . However, it is possible that ras p21 has effector proteins other than Raf-1, since ras p21 exerts multiple functions(1, 2) . The first possible effector protein of ras p21 was GAP(23) . GAP interacts with only the GTP-bound form of ras p21 and fails to interact with the effector loop mutant of ras p21. Although it has been reported that GAP has an influence downstream of ras p21 in various signaling pathways(23, 24, 25) , it is not clear whether GAP is a real effector protein because GAP acts as a negative regulator of ras p21 by stimulating the GTPase activity of ras p21(23) . Another possible effector protein of ras p21 is PI 3-kinase(26) . PI 3-kinase consists of two subunits, p85 and p110. p110 associates with the GTP-bound form of ras p21. v-ras p21 elevates phosphorylated phosphoinositide levels, products of PI 3-kinase, in COS cells, and a dominant negative mutant of ras p21 inhibits nerve growth factor-induced phosphorylated phosphoinositide production in PC12 cells. However, we have reported that platelet-derived growth factor receptor mutant, which lacks the ability to bind to PI 3-kinase, is not able to stimulate GDP/GTP exchange of ras p21 in Chinese hamster ovary cells and epithelial murine mammary gland cells and that a constitutively active form of PI 3-kinase stimulates the GDP/GTP exchange of ras p21 in Xenopus oocytes (27, 28) . These results suggest that PI 3-kinase acts upstream of ras p21. Therefore, whether GAP and PI 3-kinase are effector proteins of ras p21 might be dependent on cell types.

We have recently shown that RalGDS is a potential effector protein of ras p21(29) . RalGDS has been originally isolated by polymerase chain reaction using regions conserved between CDC25 and ste6 proteins, two GDP/GTP exchange proteins known to regulate ras p21 in Saccharomyces cerevisiae and Saccharomyces pombe, respectively(30) . RalGDS is a 115-kDa protein that shares a high homology with the region of CDC25, which is important to stimulate the GDP/GTP exchange of ras p21. However, RalGDS does not affect the GDP/GTP exchange of ras p21. Among 13 different small G proteins, RalGDS stimulates the GDP/GTP exchange only of ralA p24 and ralB p24. ral p24 has been originally isolated by probing with an oligonucleotide corresponding to one of the GTP-binding domain of ras p21 (31) . Although the function of ral p24 has not yet been understood, RalGDS has been implicated in the regulation of the GTP state of ral p24(30) . We have found that RalGDS interacts with the GTP-bound active form of ras p21 but not with the GDP-bound inactive form, that the interaction of ras p21 and RalGDS requires the effector loop of ras p21, and that RalGDS inhibits the interaction of ras p21 with Raf-1 and GAP(29) . Thus, RalGDS fulfills the criteria expected of ras p21-effector protein interactions. Two other groups have reported similar results(32, 33) .

However, we have not yet demonstrated the interaction of ras p21 and RalGDS in intact mammalian cells in response to an extracellular signal. It has not been clarified how ras p21 distinguishes these possible effector proteins. Here we demonstrate that when COS cells are treated with EGF, RalGDS can be immunoprecipitated with ras p21. Furthermore, we show that protein kinase A regulates the selectivity of ras p21-binding to either RalGDS or Raf-1.


EXPERIMENTAL PROCEDURES

Materials and Chemicals

The RalGDSb and ralB p24 cDNAs and the anti-RalGDS antibody were provided by Drs. B. W. Giddings, C. F. Albright, and R. A. Weinberg (Whitehead Institute for Biomedical Research, Cambridge, MA)(30) . The c-Ha-ras p21 cDNA, dominant negative ras p21 cDNA (ras p21 (a form of ras p21 mutant in which Ser-17 is changed to Asn)), and the hybridoma cells producing anti-ras p21 antibody (Y13-259) were provided by Dr. J. Downward (Imperial Cancer Research Institute, United Kingdom). Mammalian expression vectors, pBJ-1 and pCGN, and the mouse anti-influenza virus HA1 monoclonal antibody 12CA5 (34) were provided by Dr. Q. Hu (University of California, San Francisco, CA). pCGN was designed to express a 16-amino acid epitope from influenza virus HA fused to protein. The rabbit anti-GST polyclonal antibody was provided by Dr. Kevin Ramer (University of California, San Francisco, CA). COS-7 cells were obtained from the American Type Culture Collection. EGF was purchased from Boeringer Mannheim. A catalytic site of protein kinase A was purchased from Sigma. High-five cells were from Invitrogen (San Diego). The anti-ras p21 antibodies (Y13-238 for immunoprecipitation assay, F235 for immunoblot analysis) were from Oncogene Science Inc. (New York). [-P]ATP, [alpha-P]GTP, and [^3H]GDP were from DuPont NEN. v-ras p21 and ras p21 were synthesized by polymerase chain reaction as described previously(29) . c-ras p21 and RalGDS were purified from the cytosolic fraction of Sf9 cells and High-five cells, respectively, as described previously(29, 30) . GST fused to (1-149)Raf (amino acid 1-149) (GST-(1-149)Raf) was purified from Escherichia coli expressing GST-(1-149)Raf as described previously(35) . GST fused to ral p24 (GST-ral p24) was purified from E. coli expressing GST-ral p24. GST fused to mitogen-activated protein kinase kinase (GST-mitogen-activated protein kinase kinase) and KNERK (GST-KNERK) were purified from E. coli expressing GST-mitogen-activated protein kinase kinase and GST-KNERK, respectively, as described previously(16) . GST-KNERK was cleaved with thrombin.

Plasmid Constructions

To construct pCGN encoding RalGDS, pGAD/RalGDS (29) was digested with BamHI and EcoRI. This fragment was blunted with Klenow and inserted into pCGN, which was digested with BamHI and blunted to generate pCGN/RalGDS. To construct pBJ-1 encoding v-ras p21, ras p21, c-ras p21, and ras p21, the 0.6-kb fragments containing ras p21 and ras p21 mutants with the XbaI site upstream from the initiator methionine codon and the BamHI site downstream from the termination codon were synthesized by polymerase chain reaction. These fragments were digested with XbaI and BamHI and inserted into the XbaI- and BamHI-cut pBJ-1 to generate pBJ/v-ras p21, pBJ/ras p21, pBJ/c-ras p21, and pBJ/ras p21. To construct pGEX-2T encoding (1-149)Raf and ral p24, the 0.5- and 0.6-kilobase fragments containing (1-149)Raf and ral p24 with BamHI and EcoRI were synthesized by polymerase chain reaction. These fragments were digested with BamHI and EcoRI and inserted into the BamHI- and EcoRI-cut pGEX-2T to generate pGEX/(1-149)Raf and pGEX/ral p24.

Transient Expression of Recombinant ras p21 and RalGDS in COS Cells

COS-7 cells were cultured at 37 °C in Dulbecoo's modified Eagle's medium containing 10% calf serum, 50 µg/ml penicillin, and 50 µg/ml streptomycin. COS-7 cells (60-70% confluent on a 10-cm-diameter plate) were transfected with pCGN- and pBJ-derived constructs described above by the DEAE-dextran method(36) . 60 h after transfection, the cells were lysed, and ras p21 and RalGDS were analyzed for complex formation. To examine the complex formation of ras p21 and RalGDS by EGF, the cells were incubated in Dulbecoo's modified Eagle's medium containing 2% dialyzed serum for 24 h more. Then the cells were washed with Dulbecoo's modified Eagle's medium and stimulated with various concentrations of EGF for the indicated time. Where relevant, the cells were pretreated with forskolin for 15 min prior to EGF stimulation. After stimulation, the cells were lysed, and ras p21 and RalGDS were analyzed for complex formation.

Interaction Assay of ras p21 and RalGDS in COS Cells

COS-7 cells were lysed in 0.5 ml of lysis buffer (20 mM Tris-HCl (pH 7.5), 1% Nonidet P-40, 137 mM NaCl, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 20 µg/ml aprotinin, and 10 µg/ml leupeptin) for 1 h at 4 °C. Insoluble material was removed by centrifugation for 30 min at 4 °C at 13,000 times g, and 0.2 ml of lysate (160 µg of protein) was used for each assay. The lysates expressing RalGDS and v-ras p21, ras p21, c-ras p21, or ras p21 were prepared, and the proteins of the lysates were immunoprecipitated with the anti-ras p21 antibody. Y13-238 was used in the immunoprecipitation experiments except for Fig. 1C, where Y13-259 was used. The immunoprecipitates were washed once with lysis buffer, twice with 100 mM Tris-HCl (pH 7.5) and 0.5 M LiCl, and once with 10 mM Tris-HCl (pH 7.5). The precipitates were subjected to SDS-PAGE (12% polyacrylamide gel)(37) , transferred to nitrocellulose filters and probed with the anti-HA or anti-ras p21 antibody. The bound antibody was detected with the anti-mouse antibody conjugated to alkaline phosphatase and developed with nitro blue tetrazolium and 5-bromo-4-chloro-3-indolylphosphate (Promega, Madison). Alternatively, ECL system (Amersham Corp.) was used for detecting the complex formation of ras p21 and RalGDS by stimulation with EGF. The developed bands were quantitated by using a personal densitometer (Molecular Dynamics, Sunnyvale, CA).


Figure 1: Interaction of ras p21 and RalGDS in COS-7 cells. A, coexpression of ras p21 and RalGDS in COS cells. Aliquots (10 µl each) of lysates expressing no protein (lane 1), RalGDS alone (lane 2), both v-ras p21 and RalGDS (lane 3), or both ras p21 and RalGDS (lane 4) were probed with the anti-HA and ras p21 antibodies. B, interaction of ras p21 and RalGDS in COS cells. COS cells expressing RalGDS alone (lane 1), v-ras p21 alone (lane 2), both v-ras p21 and RalGDS (lanes 3 and 5), and both ras p21 and RalGDS (lane 4) were lysed, and the proteins of the lysates were immunoprecipitated with the anti-ras p21 antibody (Y13-238) (lanes 1-4) or nonimmune rat immunoglobulin (lane 5). The precipitates were probed with the anti-HA and ras p21 antibodies. C, inability of Y13-259 to immunoprecipitate a ras p21-RalGDS complex. COS cells expressing both v-ras p21 and RalGDS were lysed, and the proteins of the lysates were immunoprecipitated with Y13-238 (lane 1) or Y13-259 (lane 2). The precipitates were probed with the anti-HA and ras p21 antibodies. An arrowhead and an arrow indicate the positions of RalGDS and ras p21, respectively. IP, immunoprecipitation; Ig, immunoglobulin. The results shown are representative of three independent experiments.



Interaction Assay of ras p21 and RalGDS in Vitro

To make the GTPS-bound form of ras p21, c-ras p21 (20 pmol) was incubated for 10 min at 30 °C in 40 µl of reaction mixture (20 mM Tris-HCl (pH 7.5), 10 mM EDTA, 5 mM MgCl(2), 1 mM DTT, and 25 µM GTPS). After the incubation, 600 mM MgCl(2) was added at a final concentration of 15 mM. The GTPS-bound form of ras p21 was incubated for 30 min at 4 °C with RalGDS (20 pmol) in 100 µl of reaction mixture (20 mM Tris-HCl (pH 7.5), 5 mM EDTA, 10 mM MgCl(2), 0.5 mM DTT, and 25 µM GTPS) in the presence or absence of GST-(1-149)Raf. Then, the anti-ras p21 antibody (Y13-238) was added to this mixture, followed by immunoprecipitation. The precipitate was subjected to SDS-PAGE, transferred to nitrocellulose filters, and probed with the anti-RalGDS antibody.

Interaction Assay of ras p21 and Raf-1 in Vitro

The GTPS-bound form of ras p21 was made as described above and incubated for 30 min at 4 °C with GST-(1-149)Raf (20 pmol) in 100 µl of reaction mixture (20 mM Tris-HCl (pH 7.5), 5 mM EDTA, 10 mM MgCl(2), 0.5 mM DTT, and 25 µM GTPS). Then, the anti-ras p21 antibody (Y13-238) was added to this mixture, followed by immunoprecipitation. The precipitate was subjected to SDS-PAGE, transferred to nitrocellulose filters, and probed with the anti-GST antibody. Alternatively, ras p21 (2.5 pmol) was incubated for 5 min at 30 °C in 5 µl of reaction mixture (100 mM sodium phosphate (pH 6.8), 0.5 mM EDTA, 0.5 mg/ml bovine serum albumin, 0.5 mM DTT, and 0.5 µM [alpha-P]GTP (20,000-30,000 cpm/pmol)). The [alpha-P]GTP-bound form of ras p21 was further incubated with GST-(1-149)Raf for 30 min at 4 °C in 50 µl of reaction mixture (20 mM Na-Hepes (pH 7.5), 2 mM Tris-HCl (pH 7.5), 1 mM MgCl(2), 1 mg/ml bovine serum albumin, 0.1 mM DTT, and 500 µM GTP). GST-(1-149)Raf was precipitated with glutathione-Sepharose 4B, the precipitates were washed, and the remaining radioactivities were determined using scintillation counting.

Phosphorylation of ras p21, Raf-1, and RalGDS by Protein Kinase A

The purified ras p21, GST-(1-149)Raf, and RalGDS were incubated with the catalytic subunit of protein kinase A (40 units) for 20 min at 30 °C in 40 µl of reaction mixture (20 mM Tris-HCl (pH 7.5), 12 mM MgCl(2), 1 mM DTT, 100 mM NaCl, and 50 µM ATP). To detect phosphorylated bands by autoradiography, 50 µM [-P]ATP (2,000-4,000 cpm/pmol) was used instead of 50 µM ATP.

RalGDS Assay

To make [^3H]GDP-bound form of ral p24, GST-ral p24 (5 pmol) was preincubated for 10 min at 30 °C in 5 µl of reaction mixture (25 mM Tris-HCl (pH 7.5), 10 mM EDTA, 5 mM MgCl(2), 1 mM DTT, and 5 µM [^3H]GDP (3,000-4,000 cpm/pmol)). To this preincubation mixture, 45 µl of reaction mixture (55 mM Tris-HCl (pH 7.5), 11 mM MgCl(2), 1.1 mg/ml bovine serum albumin, and 110 µM GTP) containing the indicated amounts of RalGDS was added, and the mixture was further incubated for 10 min at 30 °C. Assays were quantified by rapid filtration on nitrocellulose filters(30) .

Raf-1 Activity Assay in COS Cells

COS-7 cells stimulated with EGF were lysed in 0.5 ml of lysis buffer, and 0.2 ml of lysates (160 µg of protein) were immunoprecipitated with the anti-Raf-1 antibody. The Raf-1 kinase activity was determined by incubating the Raf-1 immunoprecipitates with GST-mitogen-activated protein kinase kinase and KNERK in 30 µl of kinase reaction mixture (20 mM Tris-HCl (pH 7.5), 10 mM MgCl(2), 10 mM MnCl(2), 20 mM beta-glycerophosphate, and 50 µM [-P]ATP (1,000-2,000 cpm/pmol)) for 30 min at 25 °C(16) . After the incubation, the reaction was stopped by the addition of Laemli's loading buffer(37) , the samples were subjected to SDS-PAGE (10% polyacrylamide gel), and the phosphoproteins were visualized by autoradiography. The radioactivity incorporated in KNERK was determined using scintillation counting.

Other Assays

Protein concentrations were determined with bovine serum albumin as a standard(38) .


RESULTS

Interaction of ras p21 and RalGDS in Intact Cells

To examine whether ras p21 interacts with RalGDS in mammalian cells, we coexpressed v-ras p21 and RalGDS in COS-7 cells. RalGDS was tagged with a 16-amino acid epitope from influenza virus HA, which was recognized by the monoclonal antibody 12CA5. The expression level of transfected RalGDS in COS cells expressing RalGDS alone was similar to that in the cells coexpressing v-ras p21 and RalGDS, as assessed by immunoblotting using the anti-HA antibody (Fig. 1A, lanes 1-3). When the lysates coexpressing v-ras p21 and RalGDS were immunoprecipitated with the anti-ras p21 antibody, both ras p21 and RalGDS were detected in the ras p21 immune complex (Fig. 1B, lane 3). When the lysates expressing RalGDS alone or v-ras p21 alone were immunoprecipitated with the anti-ras p21 antibody, RalGDS was not detected (Fig. 1B, lanes 1 and 2). Neither RalGDS nor ras p21 was immunoprecipitated with nonimmune immunoglobulin from the lysates expressing both proteins (Fig. 1B, lane 5).

To characterize the interaction of ras p21 and RalGDS further, we examined the ability of RalGDS to interact with a ras p21 mutant, ras p21. ras p21 is well known as a dominant negative mutant, which has a higher affinity for GDP than GTP and strongly interacts with upstream molecules but not with downstream molecules(1, 2, 39) . The expression level of ras p21 was similar to that of v-ras p21 (Fig. 1A, lanes 3 and 4). When the lysates coexpressing ras p21 and RalGDS were immunoprecipitated with the anti-ras p21 antibody, RalGDS was not coprecipitated with ras p21 under the same conditions that were used to coprecipitate v-ras p21 and RalGDS (Fig. 1B, lanes 3 and 4). We used Y13-238 as the anti-ras p21 antibody to immunoprecipitate ras p21 for these experiments. Another antibody, Y13-259, was tested for its ability to immunoprecipitate a ras p21-RalGDS complex. Y13-259 is known to be the neutralizing antibody(1, 40) . In contrast to Y13-238, Y13-259 could not immunoprecipitate the ras p21-RalGDS complex from the lysate coexpressing v-ras p21 and RalGDS (Fig. 1C, lanes 1 and 2). Y13-238 and Y13-259 immunoprecipitated the similar amounts of ras p21 from the lysates (Fig. 1C, lanes 1 and 2). These results indicate that RalGDS makes a complex with v-ras p21 but not with ras p21 in COS cells, and the interaction of ras p21 and RalGDS requires the effector loop of ras p21. These results in COS cells are consistent with our previous observations in Sf9 cells(29) .

Interaction of ras p21 and RalGDS in Response to an Extracellular Signal

To examine whether ras p21 interacts with RalGDS in mammalian cells in response to an extracellular signal, we coexpressed c-ras p21 and RalGDS in COS cells (Fig. 2A, lane 2). Then, the cells were stimulated with EGF. EGF is known to activate ras p21 (2, 4) . RalGDS was coprecipitated with ras p21 in a dose-dependent manner of EGF (Fig. 2B). We also coexpressed RalGDS and ras p21 in COS cells (Fig. 2A, lane 3). The expression level of ras p21 was similar with that of c-ras p21. ras p21 is an effector loop mutant of ras p21, which fails to interact with effector proteins(1, 2, 12, 13, 14, 23) . RalGDS was not coprecipitated with ras p21 by stimulation with EGF (Fig. 2B). The interaction of ras p21 and RalGDS was observed within 2 min after stimulation with EGF, reached to the maximal level at 20 min, and then gradually decreased (Fig. 2C). This time course was almost the same as that of EGF-dependent Raf-1 activity to activate mitogen-activated protein kinase kinase (data not shown). In contrast, ras p21 did not make a complex with RalGDS within 60 min. These results demonstrate that ras p21 interacts with RalGDS in mammalian cells in response to an extracellular signal and that the effector loop of ras p21 is important for the interaction of ras p21 and RalGDS.


Figure 2: Interaction of ras p21 and RalGDS in COS-7 cells by stimulation with EGF. A, coexpression of c-ras p21 or ras p21 and RalGDS in COS cells. Aliquots (10 µl each) of the lysates expressing no protein (lane 1), both c-ras p21 and RalGDS (lane 2), or both ras p21 and RalGDS (lane 3) were probed with the anti-HA and ras p21 antibodies. An arrowhead and an arrow indicate the positions of RalGDS and ras p21, respectively. B, dose dependence. COS cells expressing both c-ras p21 and RalGDS (bullet) or both ras p21 and RalGDS (circle) were stimulated with the indicated concentrations of EGF for 10 min. After stimulation, the cells were lysed, and the proteins of the lysates were immunoprecipitated with the anti-ras p21 antibody. The precipitates were probed with the anti-HA antibody. ECL system was used for detection (left panel), and the developed bands were quantified by personal densitometer (right panel). An arrowhead indicates the positions of RalGDS. Ig, immunoglobulin. C, time course. COS cells expressing both c-ras p21 and RalGDS (bullet) or both ras p21 and RalGDS (circle) were stimulated with 100 ng/ml of EGF for the indicated time. After stimulation, the cells were lysed, and the proteins of the lysates were immunoprecipitated with the anti-ras p21 antibody. The precipitates were probed with the anti-HA antibody. ECL system was used for detection and the developed bands were quantified by personal densitometer. The results shown are representative of three independent experiments.



Phosphorylation of RalGDS by Protein Kinase A

The results described above taken together with our previous observations (29) strongly suggest that RalGDS is an effector protein of ras p21. Since Raf-1 is an effector protein of ras p21, we next asked how ras p21 distinguishes between RalGDS and Raf-1. It has been reported that Raf-1 is phosphorylated by protein kinase A, resulting in the inhibition of Raf-1 binding to ras p21 and Raf-1 activity(35, 41, 42, 43) . Therefore, we examined the effect of protein kinase A on the interaction of ras p21, RalGDS, and Raf-1. ras p21, GST-(1-149)Raf, and RalGDS were purified to the near homogeneity (Fig. 3A, lanes 1-3). GST-(1-149)Raf contains the ras p21-binding domain and protein kinase A-phosphorylation site(35) . ras p21 was faintly phosphorylated by the catalytic subunit of protein kinase A (Fig. 3B, lanes 1 and 2). About 0.1 mol of phosphate was incorporated into 1 mol of ras p21, as consistent with the previous observations(44, 45) . RalGDS was phosphorylated by protein kinase A as well as GST-(1-149)Raf (Fig. 3B, lanes 3-6). The phosphorylation of RalGDS by protein kinase A was a dose-dependent manner and a time-dependent manner (data not shown). About 0.7 mol of phosphate was incorporated into 1 mol of RalGDS. As consistent with the previous observations (35) , the phosphorylation of GST-(1-149)Raf reduced the ability of GST-(1-149)Raf to complex with ras p21 (Fig. 3C). However, the phosphorylation of RalGDS did not affect the interaction of RalGDS and ras p21 (Fig. 3D). RalGDS was found to stimulate the dissociation of GDP from ral p24(30) . The phosphorylation of RalGDS did not affect this activity of RalGDS (Fig. 4).


Figure 3: Phosphorylation of RalGDS by protein kinase A. A, protein staining of c-ras p21, GST-(1-149)Raf, and RalGDS. The purified c-ras p21 (lane 1), GST-(1-149)Raf (lane 2), and RalGDS (lane 3) (0.5 µg of protein each) were subjected to SDS-PAGE (12% polyacrylamide gel) and stained with Coomassie Brilliant Blue. A big arrow, a small arrow, and an arrowhead indicate the positions of ras p21, GST-(1-149)Raf, and RalGDS, respectively. B, phosphorylation of c-ras p21, GST-(1-149)Raf, and RalGDS by protein kinase A. c-ras p21 (lanes 1 and 2), GST-(1-149)Raf (lanes 3 and 4), and RalGDS (lanes 5 and 6) (2 pmol each) were incubated in the presence (lanes 1, 3, and 5) or absence (lanes 2, 4, and 6) of the catalytic subunit of protein kinase A for 20 min at 30 °C. The reaction was stopped by the addition of Laemmli's buffer. The samples were subjected to SDS-PAGE, followed by autoradiography. A big arrow, a small arrow, and an arrowhead indicate the positions of ras p21, GST-(1-149)Raf, and RalGDS, respectively. C, effect of the phosphorylation of GST-(1-149)Raf on its binding to ras p21. The unphosphorylated (circle) or phosphorylated (bullet) form of GST-(1-149)Raf (20 pmol each) was incubated with the indicated concentrations of the GTPS-bound form of ras p21 for 30 min at 4 °C. The mixtures were immunoprecipitated with the anti-ras p21 antibody, and the precipitates were probed with the anti-GST antibody. The developed bands were quantified by personal densitometer. D, effect of the phosphorylation of RalGDS on its binding to ras p21. The unphosphorylated (circle) or phosphorylated (bullet) form of RalGDS (20 pmol each) was incubated with the indicated concentrations of the GTPS-bound form of ras p21 for 30 min at 4 °C. The mixtures were immunoprecipitated with the anti-ras p21 antibody, and the precipitates were probed with the anti-RalGDS antibody. The developed bands were quantified by personal densitometer. The results shown are representative of three independent experiments.




Figure 4: Effect of the phosphorylation of RalGDS on its GDP/GTP exchange activity for ral p24. The [^3H]GDP-bound form of ral p24 (5 pmol) was incubated with the indicated concentrations of the unphosphorylated (circle) or phosphorylated (bullet) form of RalGDS for 10 min at 30 °C. The results shown are representative of three independent experiments.



Effect of the Phosphorylation of Raf-1 on Its Inhibitory Action for the Interaction of ras p21 and RalGDS in Vitro

We examined the effect of the phosphorylation of Raf-1 by protein kinase A on its inhibitory action for the interaction of ras p21 and RalGDS. GST-(1-149)Raf made a complex with ras p21 in a dose-dependent manner of GST-(1-149)Raf, and the phosphorylated form of GST-(1-149)Raf had a lower affinity for ras p21 than the unphosphorylated form (Fig. 5A). These results are consistent with the previous observations(35, 43) . GST-(1-149)Raf inhibited the interaction of ras p21 and RalGDS at an IC of about 150 nM. When GST(1-149)Raf was phosphorylated by protein kinase A, the inhibitory action of GST(1-149)Raf for the interaction of ras p21 and RalGDS was attenuated (Fig. 5B).


Figure 5: Inhibitory action of Raf-1 for the interaction of ras p21 and RalGDS. A, effect of the phosphorylation of GST-(1-149)Raf on its binding to ras p21. The [alpha-P]GTP-bound form of ras p21 (2.5 pmol) was incubated with the indicated concentrations of the unphosphorylated (circle) or phosphorylated (bullet) form of GST-(1-149)Raf for 30 min at 4 °C. The mixtures were precipitated with glutathione-Sepharose 4B, and the radioactivities of the precipitates were determined. B, effect of the phosphorylation of GST-(1-149)Raf on its inhibitory action for the interaction of ras p21 and RalGDS. The GTPS-bound form of ras p21 (10 pmol) was incubated with RalGDS (20 pmol each) in the presence of the indicated concentrations of the unphosphorylated (circle) or phosphorylated (bullet) form of GST-(1-149)Raf for 30 min at 4 °C. The mixtures were immunoprecipitated with the anti-ras p21 antibody, and the precipitates were probed with the anti-RalGDS antibody. The developed bands were quantified by personal densitometer. The results shown are representative of three independent experiments.



Effect of Protein Kinase A on the Interaction of ras p21 and RalGDS in COS Cells

Finally we checked the effect of protein kinase A on the interaction of ras p21 and RalGDS in intact cells. After COS cells overexpressing both ras p21 and RalGDS were pretreated with forskolin, the cells were stimulated with EGF, and EGF-dependent Raf-1 activity and the interaction of ras p21 with RalGDS induced by EGF were examined. Consistent with the previous observations(42, 43) , EGF-dependent Raf-1 activity was inhibited by forskolin (Fig. 6). From the results of Fig. 5, we expected that forskolin treatment would promote the EGF-dependent interaction of ras p21 and RalGDS by decreasing the competition by Raf-1. However, forskolin did not affect the interaction of ras p21 and RalGDS induced by EGF in COS cells overexpressing both ras p21 and RalGDS (Fig. 6). We thought that one of the reasons for the failure of forskolin to stimulate the interaction of these proteins might be due to overexpression of ras p21, which was enough to bind to both RalGDS and Raf-1. Therefore, we expressed RalGDS alone in COS cells and examined the interaction of endogenous ras p21 and overexpressed RalGDS. In these cells, forskolin treatment further stimulated the interaction of ras p21 and RalGDS induced by EGF (Fig. 7).


Figure 6: Effect of protein kinase A on the interaction of ras p21 and RalGDS in COS cells. COS-7 cells expressing both ras p21 and RalGDS were treated with the indicated concentrations of forskolin for 15 min and then stimulated with 100 ng/ml EGF for 10 min. The complex formation of ras p21 and RalGDS () was assayed as described in legend to Fig. 2. The amount of RalGDS bound to ras p21 was expressed as percentage of that in the cells stimulated with EGF in the absence of forskolin. Raf-1 activity (&cjs2113;) was measured using GST-mitogen-activated protein kinase kinase and KNERK as substrates. The results shown are representative of three independent experiments.




Figure 7: Stimulation of the interaction of ras p21 and RalGDS by protein kinase A in COS cells. COS-7 cells expressing RalGDS alone were treated with () or without (box) 50 µM forskolin for 15 min and then stimulated with or without 100 ng/ml EGF for 10 min. The cells were lysed, and the proteins of the lysates (2 ml, 1.6 mg of protein) were immunoprecipitated with the anti-HA antibody. The precipitates were probed with the anti-ras p21 antibody. The developed bands were quantified by personal densitometer. The results shown are the means ± S.D. of three independent experiments. *, p < 0.01.




DISCUSSION

We have demonstrated here that the interaction of ras p21 and RalGDS occurs in intact mammalian cells in response to an extracellular signal. RalGDS makes a complex with v-ras p21 but not with ras p21 in COS cells. It is believed that v-ras p21 is a GTP-bound form and that ras p21 is a GDP-bound form in intact cells(1, 2, 39) . One ras p21 antibody, Y13-238, precipitates the ras p21-RalGDS complex, but another antibody, Y13-259, does not. It is known that Y13-259 is a neutralizing antibody and that this antibody does not recognize the ras p21-effector complex(1, 2, 14, 29, 40) . Furthermore, EGF induces the complex formation of RalGDS with c-ras p21, but not with ras p21. ras p21 is an effector loop mutant of ras p21 and fails to interact with Raf-1 and GAP(11, 12, 13, 14) . These observations clearly show that RalGDS interacts with the GTP-bound form of ras p21 through the effector loop of ras p21 by stimulation with EGF in COS cells. Therefore, it is likely that RalGDS is an effector protein of ras p21 in mammalian cells

Our results suggest that RalGDS provides a potential link between ras p21 and ral p24. The results showing that one small G protein act downstream of other small G proteins has been reported(46, 47) . Genetic analysis of yeast have demonstrated that cdc42sp, a member of small G protein of S. pombe, lies downstream of ras1 in S. pombe and that CDC42, a member of small G protein of S. cerevisiae, acts downstream of RSR1, another member of small G protein of S. cerevisiae(46) . It has been also shown that rac p21 is involved in the action of rho p21 to regulate the cytoskelton(47) . Although the function of ral p24 has not yet been understood, it is possible that ral p24 acts downstream of ras p21 and that ral p24 modulates some ras p21-dependent processes.

It has been reported that RalGDS is phosphorylated in COS cells and that phosphoserine, but not phosphotyrosine, is detected in the phosphorylated RalGDS(30) . Our results show that protein kinase A phosphorylates RalGDS. But, the phosphorylation of RalGDS affects neither its interaction with ras p21 nor its GDS activity for ral p24. The physiological significance of the phosphorylation of RalGDS by protein kinase A remains to be clarified. Among many small G proteins, rap1 is known to be phosphorylated by protein kinase A(45) . The GDP/GTP exchange reaction of rap1 is regulated by Smg GDP dissociation stimulator and the phosphorylation of rap1 enhanced the Smg GDP dissociation stimulator action(48) . Although we do not known whether ral p24 is phosphorylated by protein kinase A, ral p24 has consensus sequences of phosphorylation by protein kinase A. It is intriguing to speculate that the phosphorylation of ral p24 makes it sensitive to the action of RalGDS to stimulate the GDP/GTP exchange reaction.

Evidence has accumulated that there are several effector proteins of ras p21 (9, 11-16, 23, 26, 29, 31, 32). However, it has not yet been clarified how ras p21 distinguishes these effector proteins. Our results provide one possible model. It is known that Raf-1 is phosphorylated by protein kinase A and that phosphorylation of Raf-1 reduces its affinity for ras p21(35, 41, 42, 43) . The change of the characteristics of Raf-1 by phosphorylation could be one of the mechanisms by which protein kinase A inhibits ras p21-dependent Raf-1 activation. Our results show that the phosphorylation of RalGDS by protein kinase A does not affect its binding to ras p21 under the conditions that the phosphorylation of Raf-1 by protein kinase A inhibits its binding to ras p21 in vitro. Our results also show that when Raf-1 is phosphorylated by protein kinase A, the inhibitory action of Raf-1 for the interaction of RalGDS and ras p21 is attenuated in vitro. Furthermore, our results demonstrate that protein kinase A stimulates the interaction of ras p21 and RalGDS induced by EGF under the conditions that EGF-dependent Raf-1 activity is inhibited in COS cells. Taken together with the previous observations(35, 41, 42, 43) , these results indicate that protein kinase A inhibits the signal from ras p21 to Raf-1 but not to RalGDS. Therefore, it is likely that RalGDS and Raf-1 plays a role in cross-talk between the protein kinase A system and the tyrosine kinase-ras p21 system. Further studies are necessary to clarify the definitive function of RalGDS in signal transduction.


FOOTNOTES

*
This work was supported by a grant from Daiichi Pharmaceutical Co., Ltd., and by a Cardiovascular Research Institute Comroe Fellowship. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Present address: Dept. of Biochemistry, Hiroshima University School of Medicine, 1-2-3 Kasumi, Minami-ku, Hiroshima 734, Japan.

To whom correspondence should be addressed: Cardiovascular Research Inst., and Daiichi Research Center, University of California, 505 Parnassus Ave., Box 0130, San Francisco, CA 94143-0130. Tel.: 415-476-4402; Fax: 415-476-0429.

(^1)
The abbreviations used are: EGF, Epidermal growth factor; Grb2, growth factor receptor-binding protein 2; PI, phosphatidylinositol; GAP, GTPase activating protein; KNERK, kinase-negative mutant of extracellular signal-regulated kinase; PAGE, polyacrylamide gel electrophoresis; HA, hemagglutinin; GST, glutathione S-transferase; DTT, dithiothreitol; GTPS, guanosine 5`-(3-O-thio)triphosphate.


ACKNOWLEDGEMENTS

We thank Drs. B. W. Giddings, C. F. Albright, and R. A. Weinberg for the RalGDSb and ralB p24 cDNAs and the RalGDS antibody and Dr Q. Hu for the mammalian expression vectors and the anti-HA antibody.


REFERENCES

  1. Barbacid, M. (1987) Annu. Rev. Biochem. 56, 779-827 [CrossRef][Medline] [Order article via Infotrieve]
  2. Lowy, D. R., and Willumsen, B. M. (1993) Annu. Rev. Biochem. 62, 851-891 [CrossRef][Medline] [Order article via Infotrieve]
  3. Fantl, W. J., Johnson, D. E., and Williams, L. T. (1993) Annu. Rev. Biochem. 62, 453-481 [CrossRef][Medline] [Order article via Infotrieve]
  4. Satoh, T., Nakafuku, M., and Kaziro, Y. (1992) J. Biol. Chem. 267, 24149-24152 [Free Full Text]
  5. Schlessinger, J., and Ullrich, A. (1992) Neuron 9, 383-391 [Medline] [Order article via Infotrieve]
  6. Chardin, P., Camonis, J. H., Gale, N. W., van Aelst, L., Schlessinger, J., Wigler, M. H., and Bar-Sagi, D. (1993) Science 260, 1338-1343 [Medline] [Order article via Infotrieve]
  7. Egan, S. E., Giddings, B. W., Brooks, M. W., Buday, L., Sizeland, A. M., and Weinberg, R. A. (1993) Nature 363, 45-51 [CrossRef][Medline] [Order article via Infotrieve]
  8. Rozakis-Adcock, M., Fernley, R., Wade, J., Pawson, T., and Bowtell, D. (1993) Nature 363, 83-85 [CrossRef][Medline] [Order article via Infotrieve]
  9. Avruch, J., Zhang, X. F., and Kyriakis, J. M. (1994) Trends Biochem. Sci. 19, 279-283 [CrossRef][Medline] [Order article via Infotrieve]
  10. Johnson, G. L., and Vaillancourt, R. R. (1994) Curr. Opin. Cell Biol. 6, 230-238 [Medline] [Order article via Infotrieve]
  11. Moodie, S. A., Willumsen, B. M., Weber, M. J., and Wolfman, A. (1993) Science 260, 1658-1661 [Medline] [Order article via Infotrieve]
  12. Zhang, X., Settleman, J., Kyriakis, J. M., Takeuchi-Suzuki, E., Elledge, S. J., Marshall, M. S., Bruder, J. T., Rapp, U. R., and Avruch, J. (1993) Nature 364, 308-313 [CrossRef][Medline] [Order article via Infotrieve]
  13. Vojtek, A. B., Hollenberg, S. M., and Cooper, J. A. (1993) Cell 74, 205-214 [Medline] [Order article via Infotrieve]
  14. Koide, H., Satoh, T., Nakafuku, M., and Kaziro, Y. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8683-8686 [Abstract/Free Full Text]
  15. Macdonald, S. G., Crews, C. M., Wu, L., Driller, J., Clark, R., Erikson, R. L., and McCormick, F. (1993) Mol. Cell. Biol. 13, 6615-6620 [Abstract]
  16. Kikuchi, A., and Williams, L. T. (1994) J. Biol. Chem. 269, 20054-20059 [Abstract/Free Full Text]
  17. Dent, P., Haser, W., Haystead, T. A., Vincent, L. A., Roberts, T. M., and Sturgill, T. W. (1992) Science 257, 1404-1407 [Medline] [Order article via Infotrieve]
  18. Howe, L. R., Leevers, S. J., Gomez, N., Nakielny, S., Cohen, P., and Marshall, C. J. (1992) Cell 71, 335-342 [Medline] [Order article via Infotrieve]
  19. Kyriakis, J. M., App, H., Zhang, X. F., Banerjee, P., Brautigan, D. L., Rapp, U. R., and Avruch, J. (1992) Nature 358, 417-421 [CrossRef][Medline] [Order article via Infotrieve]
  20. Dickson, B., Sprenger, F., Morrison, D., and Hafen, E. (1992) Nature 360, 600-603 [CrossRef][Medline] [Order article via Infotrieve]
  21. Kolch, W., Heidecker, G., Lloyd, P., and Rapp, U. R. (1991) Nature 349, 426-428 [CrossRef][Medline] [Order article via Infotrieve]
  22. Wood, K. W., Sarnecki, C., Roberts, T. M., and Blenis, J. (1992) Cell 68, 1041-1050 [Medline] [Order article via Infotrieve]
  23. Polakis, P., and McCormick, F. (1993) J. Biol. Chem. 268, 9157-9160 [Abstract/Free Full Text]
  24. Medema, R. H., de Laat, W. L., Martin, G. A., McCormick, F., and Bos, J. L. (1992) Mol. Cell. Biol. 12, 3425-3430 [Abstract]
  25. Yatani, A., Okabe, K., Polakis, P., Halenbeck, R., McCormick, F., and Brown, A. M. (1990) Cell 61, 769-776 [Medline] [Order article via Infotrieve]
  26. Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., and Downward, J. (1994) Nature 370, 527-532 [CrossRef][Medline] [Order article via Infotrieve]
  27. Satoh, T., Fantl, W. J., Escobedo, J. A., Williams, L. T., and Kaziro, Y. (1993) Mol. Cell. Biol. 13, 3706-3713 [Abstract]
  28. Hu, Q., Klippel, A., Muslin, A. J., Fantl, W. J., and Williams, L. T. (1995) Science 268, 100-102 [Medline] [Order article via Infotrieve]
  29. Kikuchi, A., Demo, S. D., Ye, Z. H., Chen, Y. W., and Williams, L. T. (1994) Mol. Cell. Biol. 14, 7483-7491 [Abstract]
  30. Albright, C. F., Giddings, B. W., Liu, J., Vito, M., and Weinberg, R. A. (1993) EMBO J. 12, 339-347 [Abstract]
  31. Chardin, P., and Tavitian, A. (1986) EMBO J. 5, 2203-2208 [Abstract]
  32. Hofer, F., Fields, S., Schneider, C., and Martin, S. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 11089-11093 [Abstract/Free Full Text]
  33. Spaargaren, M., and Bischoff, J. R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 12609-12613 [Abstract/Free Full Text]
  34. Wilson, I. A., Niman, H. L., Houghten, R. A., Cherenson, A. R., Connolly, M. L., and Lerner, R. A. (1984) Cell 37, 767-778 [Medline] [Order article via Infotrieve]
  35. Chuang, E., Barnard, D., Hettich, L., Zhang, X. F., Avruch, J., and Marshall, M. S. (1994) Mol. Cell. Biol. 14, 5318-5325 [Abstract]
  36. Gorman, C. (1985) DNA Cloning, a Practical Approach (Glover, D. M., ed) Vol. 2, IRL Press, Oxford, United Kingdom
  37. Laemmli, U. K. (1970) Nature 227, 680-685 [Medline] [Order article via Infotrieve]
  38. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254 [CrossRef][Medline] [Order article via Infotrieve]
  39. Farnsworth, C. L., and Feig, L. A. (1991) Mol. Cell. Biol. 11, 4822-4829 [Medline] [Order article via Infotrieve]
  40. Willumsen, B. M., Papageorge, A. G., Kung, H.-F., Bekesi, E., Robins, T., Johnsen, M., Vass, W. C., and Lowy, D. R. (1986) Mol. Cell. Biol. 6, 2646-2654 [Medline] [Order article via Infotrieve]
  41. Graves, L. M., Bornfeldt, K. E., Raines, E. W., Potts, B. C., Macdonald, S. G., Ross, R., and Krebs, E. G. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10300-10304 [Abstract]
  42. Cook, S. J., and McCormick, F. (1993) Science 262, 1069-1072 [Medline] [Order article via Infotrieve]
  43. Wu, J., Dent, P., Jelinek, T., Wolfman, A., Weber, M. J., and Sturgill, T. W. (1993) Science 262, 1065-1069 [Medline] [Order article via Infotrieve]
  44. Saikumar, P., Ulsh, L. S., Clanton, D. J., Huang, K. P., and Shih, T. Y. (1988) Oncogene Res. 3, 213-222 [Medline] [Order article via Infotrieve]
  45. Kawata, M., Kikuchi, A., Hoshijima, M., Yamamoto, K., Hashimoto, E., Yamamura, H., and Takai, Y. (1989) J. Biol. Chem. 264, 15688-15695 [Abstract/Free Full Text]
  46. Chang, E. C., Barr, M., Wang, Y., Jung, V., Xu, H. P., and Wigler, M. H. (1994) Cell 79, 131-141 [Medline] [Order article via Infotrieve]
  47. Ridley, A. J., Paterson, H. F., Johnston, C. L., Diekmann, D., and Hall, A. (1992) Cell 70, 401-410 [Medline] [Order article via Infotrieve]
  48. Hata, Y., Kaibuchi, K., Kawamura, S., Hiroyoshi, M., Shirataki, H., and Takai, Y. (1991) J. Biol. Chem. 266, 6571-6577 [Abstract/Free Full Text]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.